Cerulean Pharmaceuticals Receives $24,000,000 Series C Funding Round

  • Feed Type
  • Date
    11/15/2010
  • Company Name
    Cerulean Pharmaceuticals
  • Mailing Address
    840 Memorial Drive 5th Floor Cambridge, MA 02139
  • Company Description
    Within the field of nanopharmaceuticals, Cerulean Pharma is uniquely focused on a next-generation approach we call Nanobiology. Cerulean’s nanobiology-based drug development is based on a deep understanding of the complex biological microenvironment of human disease combined with engineering therapies on a nanoscale, enabling the creation of breakthrough drugs that optimally target the root causes of disease.
  • Website
    http://www.ceruleanrx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $24,000,000
  • Transaction Round
    Series C
  • Proceeds Purposes
    Cerulean plans to use the capital to advance its CRLX101development candidate into a randomized Phase II trial as a non-small cell lung cancer drug.
  • M&A Terms
  • Venture Investor
    Lilly Ventures
  • Venture Investor
    Polaris Venture Partners
  • Venture Investor
    Venrock
  • Venture Investor
    Lux Capital
  • Venture Investor
    Bessemer Venture Partners

By posting a comment, you agree to our terms and conditions.